Abstract
Background: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy Objective: To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). Methods: This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk-benefit balance. Results: Seven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in sub-populations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines, and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus. Conclusion: This first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS.
| Dokumententyp: | Zeitschriftenartikel | 
|---|---|
| Fakultät: | Medizin > Munich Cluster for Systems Neurology (SyNergy) | 
| Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit | 
| URN: | urn:nbn:de:bvb:19-epub-117270-3 | 
| Sprache: | Englisch | 
| Dokumenten ID: | 117270 | 
| Datum der Veröffentlichung auf Open Access LMU: | 07. Jun. 2024 15:43 | 
| Letzte Änderungen: | 11. Jun. 2024 14:06 | 
| DFG: | Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198 | 
 
		 
	 
    



